A Cambridge study on cannabis and stroke has been circulating again this week. It was first published in January, so the numbers people are seeing now are the same as those from March.

What?

Megan Ritson and colleagues looked at data from 32 studies, covering more than 100 million people. Of these, 19 studies gave 24 estimates about cannabis. When all the data was combined, cannabis was linked to 37% higher odds of stroke, cocaine to 96%, and amphetamines to 122%. In their main analysis, opioids did not show a significant link overall.

The cannabis studies had very mixed results. On the standard measure of how much studies disagree with each other, they came out at 99%, which is about as inconsistent as a meta-analysis can get. The authors found that smaller studies influenced the results, and after adjusting for this, the cannabis figure dropped from 37% to 12%. Only 14 of the 32 studies clearly showed that drug use happened before the stroke.

So what?

The study does not show how the risk changes with different doses or how often someone uses cannabis. Its strongest evidence is about cannabis use disorder, which means problematic or dependent use. This is very different from using cannabis occasionally, but the paper also cannot estimate the risk for people who use it only sometimes.

The genetic analysis suggests that cannabis use disorder might cause stroke, but it focused on genetic risk for cannabis use disorder, not just general cannabis use. For people under 55, the figure was 14% higher odds, but this is similar to the result for all ages. The authors say there was no significant difference by age.

For me, this study is a reminder to watch for patterns. If you find yourself using cannabis every night to help you sleep, it’s worth paying attention. In the 2024 National Health Interview Survey of 31,509 adults, 3.7% said they used marijuana or CBD most days or every day for sleep. A National Sleep Foundation survey of 1,367 adults found that current users still slept worse than nonusers, though it didn’t show whether cannabis helped. A 2025 review looked at 18 sleep-lab studies, and in the 9 that could be combined, there was no consistent change in sleep duration, how long it took to fall asleep, how much of the night was spent asleep, or sleep stages.

Now what?

Five questions are more helpful than any number this study could provide.

  • How many nights out of the last 30?
  • Has the dose gone up?
  • Can you sleep without it?
  • Have you tried to cut down and failed?
  • Are you carrying on despite worse sleep, daytime fog or something else?

Then three things worth doing regardless of your answers.

  • If you have ongoing insomnia, address it directly. CBT-I is the best first treatment, even before trying medication. Two key parts of CBT-I are waking up at the same time every day and getting out of bed if you can’t sleep, but the full program includes more steps.
  • Check your average blood pressure with proper home readings. No matter how cannabis fits in, blood pressure is the main stroke risk factor you can control.
  • If you decide to take a break, expect the first few days to be the hardest, and remember that withdrawal can last several weeks. In a national sample of people who used cannabis at least three times a week, 12% had withdrawal syndrome, and 68% of those had trouble sleeping. This is a self-test, not a result from the stroke study.

If you use cannabis just once a month, this study cannot tell you your risk. The genetic evidence is about cannabis use disorder, and the other studies did not track use often enough to set a safe limit.

I wrote in detail about sleep problems in July, including why most effective solutions are not for sale. You can read it here: [archive URL needed]

This paper is a warning about problematic cannabis use. It’s more helpful to ask yourself the five questions than to focus on a number the study never actually tested.

Stay healthy.

Andre

Editor's note

Editorial clarification and evidence update

The Upward ARC is an educational newsletter for a general audience, not a medical publication. It may use ordinary-language metaphors and simplifications to make complex evidence readable. Those phrases are not clinical terminology. The editorial standard remains unchanged: do not fabricate, cite falsely, hide important uncertainty, or simplify a point so far that it changes the practical meaning.

Updated September 3, 2026. The historical edition above remains unchanged.

What the 12% estimate means: The review's main observational estimate was 37% higher odds of stroke, with very high between-study heterogeneity. The 12% figure came from a trim-and-fill sensitivity analysis that estimated missing small studies. It is not a known corrected effect, and the underlying studies did not provide a consistent dose or frequency threshold. [1]

What the genetic analysis can show: The Mendelian-randomization analysis used genetic liability to cannabis use disorder, not a measured nightly dose. Its results support a possible causal relationship under the method's assumptions. They do not prove that cannabis caused a stroke in an individual or establish a safe exposure level. [1]

The sleep evidence remains limited: The US estimate cited in the edition counted adults using marijuana or CBD for sleep most days or every day. It measured prevalence, not benefit. A 2025 review of laboratory sleep studies found no consistent improvement in sleep duration, latency, wake time, efficiency or sleep stages, while evidence during withdrawal was more consistent for disturbed sleep. [2]

When CBT-I is first-line care: Cognitive behavioral therapy for insomnia is recommended as first-line treatment for chronic insomnia. That recommendation does not mean every short period of poor sleep needs formal CBT-I. Persistent symptoms, daytime impairment or signs of another sleep or mental-health condition deserve clinical assessment. [3]

The missing archive link: The sent edition contained the placeholder '[archive URL needed]'. The intended July article is I Fall Asleep in Ninety Seconds. This One's for Everyone Who Can't. [4]

References

  1. Ritson et al. Cannabis use and stroke risk: a systematic review, meta-analysis and Mendelian randomization study. International Journal of Stroke, 2026.
  2. Suraev et al. The effects of cannabis and cannabinoids on sleep: a systematic review and meta-analysis of polysomnographic studies. 2025.
  3. American College of Physicians. ACP recommends cognitive behavioral therapy as initial treatment for chronic insomnia.
  4. The Upward ARC archive. I Fall Asleep in Ninety Seconds. This One's for Everyone Who Can't.

For informational and educational purposes only. This page does not provide individual medical advice, diagnosis, or treatment. Read the full medical disclaimer.